CA2850357A1 - Treatment of obesity and obesity-related disorders by pharmacological targeting of kv1.3 potassium channels - Google Patents

Treatment of obesity and obesity-related disorders by pharmacological targeting of kv1.3 potassium channels Download PDF

Info

Publication number
CA2850357A1
CA2850357A1 CA2850357A CA2850357A CA2850357A1 CA 2850357 A1 CA2850357 A1 CA 2850357A1 CA 2850357 A CA2850357 A CA 2850357A CA 2850357 A CA2850357 A CA 2850357A CA 2850357 A1 CA2850357 A1 CA 2850357A1
Authority
CA
Canada
Prior art keywords
aeeac
chemical entity
shk toxin
pmp
shk
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2850357A
Other languages
English (en)
French (fr)
Inventor
George K. Chandy
Sanjeev Kumar Upadhayay
Ping H. Wang
Paolo Sassone Corsi
Kristin Lynn-Eckel Mahan
Shawn Iadonato
Joseph MUKERGEE
Reza M. Mirbolooki
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California, San Diego
Kv1.3 Therapeutics Inc
Original Assignee
University of California, San Diego
Kineta One LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California, San Diego, Kineta One LLC filed Critical University of California, San Diego
Publication of CA2850357A1 publication Critical patent/CA2850357A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1767—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43595—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from coelenteratae, e.g. medusae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA2850357A 2011-10-03 2012-10-02 Treatment of obesity and obesity-related disorders by pharmacological targeting of kv1.3 potassium channels Abandoned CA2850357A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161542751P 2011-10-03 2011-10-03
US61/542,751 2011-10-03
PCT/US2012/058495 WO2013052507A1 (en) 2011-10-03 2012-10-02 TREATMENT OF OBESITY AND OBESITY-RELATED DISORDERS BY PHARMACOLOGICAL TARGETING OF Kv1.3 POTASSIUM CHANNELS

Publications (1)

Publication Number Publication Date
CA2850357A1 true CA2850357A1 (en) 2013-04-11

Family

ID=48044112

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2850357A Abandoned CA2850357A1 (en) 2011-10-03 2012-10-02 Treatment of obesity and obesity-related disorders by pharmacological targeting of kv1.3 potassium channels

Country Status (16)

Country Link
US (2) US20150072940A1 (enExample)
EP (1) EP2763702A4 (enExample)
JP (1) JP2014531469A (enExample)
KR (1) KR20140108518A (enExample)
CN (1) CN103987408A (enExample)
AU (1) AU2012318736A1 (enExample)
BR (1) BR112014008065A2 (enExample)
CA (1) CA2850357A1 (enExample)
HK (1) HK1201048A1 (enExample)
IL (1) IL231873A0 (enExample)
IN (1) IN2014CN03333A (enExample)
MX (1) MX2014004029A (enExample)
RU (1) RU2014117558A (enExample)
SG (1) SG11201401193XA (enExample)
TW (1) TW201321403A (enExample)
WO (1) WO2013052507A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2474316B1 (en) * 2004-10-07 2016-04-06 The Regents of The University of California Analogs of shk toxin and their uses in selective inhibition of kv1.3 potassium channels
TW201542231A (zh) * 2011-06-06 2015-11-16 Kineta One Llc 以ｓｈｋ為主之醫藥組合物及其製備方法及用途
IN2014CN03333A (enExample) 2011-10-03 2015-07-03 Univ California
JP7211704B2 (ja) * 2015-01-29 2023-01-24 ノヴォ ノルディスク アー／エス Ｇｌｐ－１アゴニスト及び腸溶コーティングを含む錠剤
TWI701249B (zh) 2015-03-13 2020-08-11 德商４Ｓｃ製藥公司 Ｋv１.３抑制劑及其醫學應用
TWI698438B (zh) 2015-03-13 2020-07-11 德商４Ｓｃ製藥公司 Ｋv１.３抑制劑及其醫學應用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5453270A (en) 1992-03-30 1995-09-26 Hypermetabolic Therapies, Inc. Pharmaceutical composition and method for hypermetabolic weight loss
US6077680A (en) * 1996-11-27 2000-06-20 The University Of Florida ShK toxin compositions and methods of use
WO1999013895A1 (en) * 1997-09-17 1999-03-25 University Of Florida Polypeptide compositions that inhibit potassium channel activity and uses therefor
JP3207823B2 (ja) 1999-04-28 2001-09-10 リノール油脂株式会社 共役リノール酸を有効成分とする褐色脂肪増加剤
US6616944B2 (en) 2000-03-08 2003-09-09 Medinnova Gesellschaft Fur Medizinsche Innovationen Aus Adkademischer Forschung Mbh Self-assembling colloidal carriers for protein delivery
US6861405B2 (en) * 2001-06-12 2005-03-01 Yale University Compositions and methods relating to glucose metabolism, weight control, and food intake
EP2474316B1 (en) 2004-10-07 2016-04-06 The Regents of The University of California Analogs of shk toxin and their uses in selective inhibition of kv1.3 potassium channels
US7833979B2 (en) * 2005-04-22 2010-11-16 Amgen Inc. Toxin peptide therapeutic agents
RU2008109911A (ru) * 2005-08-17 2009-09-27 Зольвай Фармасьютикалз Гмбх (De) Способ применения соединений, ингибирующих калиевые каналы
TW201026708A (en) * 2008-12-12 2010-07-16 Solvay Pharm Bv Spiro azepane-oxazolidinones as Kv1.3 potassium channel blockers
IN2014CN03333A (enExample) 2011-10-03 2015-07-03 Univ California

Also Published As

Publication number Publication date
EP2763702A1 (en) 2014-08-13
BR112014008065A2 (pt) 2019-09-24
KR20140108518A (ko) 2014-09-11
HK1201048A1 (en) 2015-08-21
EP2763702A4 (en) 2015-04-15
SG11201401193XA (en) 2014-05-29
AU2012318736A1 (en) 2014-05-22
US20170095530A1 (en) 2017-04-06
US20150072940A1 (en) 2015-03-12
MX2014004029A (es) 2014-08-01
RU2014117558A (ru) 2015-11-10
IL231873A0 (en) 2014-05-28
JP2014531469A (ja) 2014-11-27
TW201321403A (zh) 2013-06-01
IN2014CN03333A (enExample) 2015-07-03
US9878006B2 (en) 2018-01-30
CN103987408A (zh) 2014-08-13
WO2013052507A1 (en) 2013-04-11

Similar Documents

Publication Publication Date Title
US9878006B2 (en) Treatment of obesity and obesity related disorders by pharmalogical targeting of Kv1.3 potassium channels
JP5820349B2 (ja) 膵臓ポリペプチドファミリーモチーフ、ポリペプチドおよびこれらを含む方法
JP5743371B2 (ja) 膵臓ポリペプチドファミリーモチーフ、ポリペプチドおよびこれらを含む方法
ES2502218T3 (es) Análogos de glucagón
TWI608013B (zh) 升糖素類似物
US20250188124A1 (en) Peptide compositions
KR101687037B1 (ko) 성기능 장애 치료용 멜라노코르틴 수용체-특이적 펩티드
EP3827015A1 (en) Gip/glp1 co-agonist compounds
EP2823823B1 (en) Polypeptides for the preparation of drugs for treatment or prevention of rheumatoid arthritis
BR112015001451B1 (pt) Composto, construção de ácido nucleico, vetor de expressão, célula hospedeira, composição farmacêutica, utilização de um composto ou de seu sal ou solvato farmaceuticamente aceitável
TW201605888A (zh) Ｇｉｐ－ｇｌｐ－１雙重促效劑化合物及方法
BR112019011859A2 (pt) agonista duplo de glp-1/glp-2, composição, método para aumentar massa intestinal, método de profilaxia ou tratamento de má-absorção intestinal e uso de um agonista duplo
US20200276275A1 (en) Therapies for Obesity, Diabetes and Related Indications
CA3073011C (en) Acylated oxyntomodulin peptide analog
CN107636010A (zh) 酰化胰高血糖素类似物
KR20120092089A (ko) 멜라노코르틴 수용체-특이적 펩티드
US20240270821A1 (en) Gip/glp1/gcg tri-receptor agonists and uses thereof
CN102574904A (zh) 赋予了经粘膜吸收性的胃动素样肽化合物
CN103626866B (zh) 胰多肽家族基序、包含该基序的多肽和方法
US20150197550A1 (en) Therapeutic Uses of Dogfish Glucagon and Analogues Thereof
KR20220102128A (ko) 신규 그렐린 유사체 및 이를 함유하는 아밀로이드 베타 응집 관련 질환의 예방 또는 치료용 약학 조성물

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20181002